Maintenance of Remission with Tofacitinib in Patients With Ulcerative Colitis: Subpopulation Analysis from an Open-Label, Long-Term Extension Study

被引：1
|
作者：
Jean-Frederic, Colombel [1 ]
Walter, Reinisch [2 ]
Mark, Osterman T. [3 ]
Andrew, Thorpe J. [4 ]
Chudy, Nduaka, I [4 ]
Zhang Haiying [4 ]
Nervin, Lawendy [4 ]
Gary, Friedman S. [4 ]
Su Chinyu [4 ]
机构：
[1] Icahn Sch Med Mt Sinai, Dr Henry D Janowitz Div Gastroenterol, New York, NY 10029 USA
[2] Med Univ Vienna, Dept Internal Med 3, Vienna, Austria
[3] Penn Presbyterian Med Ctr, Div Gastroenterol, Philadelphia, PA USA
[4] Pfizer Inc, Collegeville, PA USA
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2018年 / 113卷
关键词：
D O I：
10.14309/00000434-201802001-00015
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P-015
引用
收藏
页码：S4 / S4
页数：1
相关论文
共 50 条
  • [21] Maintenance of Remission With Tofacitinib Therapy in Patients With Ulcerative Colitis
    Colombel, Jean-Frederic
    Osterman, Mark T.
    Thorpe, Andrew J.
    Salese, Leonardo
    Nduaka, Chudy I.
    Zhang, Haiying
    Lawendy, Nervin
    Friedman, Gary S.
    Quirk, Daniel
    Su, Chinyu
    Reinisch, Walter
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2022, 20 (01) : 116 - +
  • [22] SAFETY OF UPADACITINIB IN ULCERATIVE COLITIS: LONG-TERM DATA FROM THE PHASE 3 OPEN-LABEL EXTENSION STUDY (U-ACTIVATE)
    Panaccione, Remo
    Lichtenstein, Gary R.
    Nakase, Hiroshi
    Armuzzi, Alessandro
    Kucharzik, Torsten
    Levy, Gweneth
    Palac, Hannah
    Kujawski, Michelle
    Klaff, Justin
    Cheon, Jae Hee
    [J]. GASTROENTEROLOGY, 2023, 164 (06) : S1100 - S1100
  • [23] Safety of upadacitinib in ulcerative colitis: Long-term data from the phase 3 open-label extension study (U-ACTIVATE)
    Panaccione, R.
    Lichtenstein, G.
    Nakase, H.
    Armuzzi, A.
    Kucharzik, T.
    Levy, G.
    Palac, H.
    Kujawski, M.
    Klaff, J.
    Cheon, J. H.
    [J]. JOURNAL OF CROHNS & COLITIS, 2023, 17 : 644 - 646
  • [24] CLINICAL OUTCOMES OF RHEUMATOID ARTHRITIS PATIENTS RECEIVING TOFACITINIB MONOTHERAPY IN THE OPEN-LABEL LONG-TERM EXTENSION
    Fleischmann, R.
    Wollenhaupt, J.
    Wang, L.
    Maniccia, A.
    Kwok, K.
    Takiya, L.
    van Vollenhoven, R.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 259 - 260
  • [25] Health-Related Quality of Life Outcomes With Tofacitinib Treatment in Patients With Ulcerative Colitis in the Open-Label Extension Study, OCTAVE Open
    Biedermann, Luc
    Dubinsky, Marla C.
    Vermeire, Severine
    Fellmann, Marc
    Gardiner, Sean
    Hur, Peter
    Mundayat, Rajiv
    Panes, Julian
    Rubin, David T.
    [J]. INFLAMMATORY BOWEL DISEASES, 2022, : 1370 - 1379
  • [26] Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study
    Nash, Peter
    Coates, Laura C.
    Kivitz, Alan
    Mease, Philip J.
    Gladman, Dafna D.
    Covarrubias-Cobos, Jose A.
    Fitzgerald, Oliver
    Fleishaker, Dona
    Wang, Cunshan
    Wu, Joseph
    Hsu, Ming-Ann
    Menon, Sujatha
    Fallon, Lara
    Romero, Ana Belen
    Kanik, Keith S.
    [J]. RHEUMATOLOGY AND THERAPY, 2020, 7 (03) : 553 - 580
  • [27] Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study
    Peter Nash
    Laura C. Coates
    Alan J. Kivitz
    Philip J. Mease
    Dafna D. Gladman
    José A. Covarrubias-Cobos
    Oliver FitzGerald
    Dona Fleishaker
    Cunshan Wang
    Joseph Wu
    Ming-Ann Hsu
    Sujatha Menon
    Lara Fallon
    Ana Belén Romero
    Keith S. Kanik
    [J]. Rheumatology and Therapy, 2020, 7 : 553 - 580
  • [28] Efficacy of tofacitinib dose escalation to 10 mg BID in patients with UC after completing maintenance therapy in remission and losing response: Data from OCTAVE open-label, long-term extension study
    Rubin, D. T.
    Dubinsky, M. C.
    Panes, J.
    Wu, D. C.
    Lawendy, N.
    Guo, X.
    Lai, C.
    Kwok, K.
    Su, C.
    Salese, L.
    [J]. JOURNAL OF CROHNS & COLITIS, 2020, 14 : S112 - S113
  • [29] Tofacitinib for the Treatment of Patients with Juvenile Idiopathic Arthritis: An Interim Analysis of Data up to 5.5 Years from an Open-label, Long-term Extension Study
    Brunner, Hermine I.
    Akikusa, Jonathan
    Al-Abadi, Eslam
    Bohnsack, John
    Boteanu, Alina Lucica
    Chedeville, Gaelle
    Cuttica, Ruben
    De La Pena, Wendy
    Jung, Lawrence
    Kasapcopur, Ozgur
    Kobusinska, Katarzyna
    Schulert, Grant
    Neiva, Claudia
    Rivas-Chacon, Rafael
    Rodriguez, Juan Cruz Rizo
    Vazquez-Del Mercado, Monica
    Wagner-Weiner, Linda
    Weiss, Jennifer E.
    Wouters, Carine
    Suehiro, Ricardo M.
    Posner, Holly
    Wouters, Ann
    Kanik, Keith S.
    Luo, Zhen
    Martini, Alberto
    Lovell, Daniel J.
    Ruperto, Nicolino
    [J]. ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [30] Histological remission is predictive of improved clinical outcomes in patients with ulcerative colitis: results from the TOUCHSTONE open-label extension
    Sandborn, W.
    Feagan, B.
    D'Haens, G.
    Levesque, B.
    Pai, R.
    Hanauer, S.
    Wolf, D.
    Vermeire, S.
    Ghosh, S.
    Li, C.
    Penenberg, D.
    Aranda, R.
    Olson, A.
    [J]. JOURNAL OF CROHNS & COLITIS, 2017, 11 : S9 - S9
12345